3-NT(3-Nitrotyrosine) ELISA Kit

Description

Alternative Names:	Â 3-Nitro-L-Tyrosine; 3-Nitrotyrosine; Nitrotyrosine
Catalogue No.	6687ELK
Size	96T
Reactivity	General
Range	4.69-300 ng/mL
Sensitivity	1.35 ng/mL
Assay Type	Competitive Inhibition
Sample Type	serum, plasma and other biological fluids
Assay Length	2h
Research Area	Metabolic pathway; Infection immunity; Rheumatology;
Test principle	This assay employs the competitive inhibition enzyme immunoassay tech provided in this kit has been pre-coated with Nitrotyrosine(NT) protein. St added to the appropriate microtiter plate wells then with a biotin-conjugat Nitrotyrosine(NT). Next,Avidin conjugated to Horseradish Peroxidase (HR microplate well and incubated. After TMB substrate solution is added. Th is terminated by the addition of sulphuric acid solution and the color chan spectrophotometrically at a wavelength of 450nm Â± 10nm. The concent the samples is then determined by comparing the OD of the samples to t

Image not found or type unknown

Standard Curve

CONCENTRATION (NG/ML)	OD	
300.00	0.217	â€”
150.00	0.467	â€”
75.00	0.793	â€”
37.50	0.967	â€”
18.75	1.236	â€”
9.38	1.596	â€”
4.69	1.861	â€”
0.00	2.265	â€”

Precision

Intra-assay Precision (Precision within an assay)ï¼šCV%<8%

Three samples of known concentration were tested twenty times on one
precision.

Inter-assay Precision (Precision between assays)ï¼šCV%<10%

Three samples of known concentration were tested in forty separate assa
precision.

Recovery

Matrices listed below were spiked with certain level of recombinant 3-NT
calculated by comparing the measured value to the expected amount of

MATRIX	RECOVERY RANGE
serum(n=5)	92-107%
EDTA plasma(n=5)	87-99%
Heparin plasma(n=5)	78-92%

Linearity

The linearity of the kit was assayed by testing samples spiked with appro
and their serial dilutions. The results were demonstrated by the percenta
to the expected.

MATRIX	1:2	1:4	
serum(n=5)	86-93%	91-105%	88
EDTA plasma(n=5)	85-95%	79-96%	89
Heparin plasma(n=5)	87-96%	81-93%	86

For Research Use Only

Date Created
2024/07/03